Where PRO Strategy Goes Wrong: Therapeutic Area Fit, Capture Frequency, And The Implementation Gap That Takes Years To Surface

As trials become more decentralized and evidence expectations rise, organizations that treat patient-reported outcomes (PROs) and clinical outcome assessments (COAs) as core strategic infrastructure will be better positioned to demonstrate a meaningful therapeutic impact. Clinical trials are increasingly expected to capture not only whether a treatment works, but how it changes daily life and quality of care. That shift is forcing organizations to rethink how COA strategy is designed from the earliest stages of development.

A strong PRO and COA strategy is no longer just about selecting the right instruments. It is about designing studies that capture meaningful patient experience data in a way that is scalable, reliable, and actionable for regulators, sponsors, and clinicians alike. When integrated effectively, these measures strengthen both the scientific and commercial value of a trial.